Vincent Chow

829 total citations
44 papers, 639 citations indexed

About

Vincent Chow is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Vincent Chow has authored 44 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 22 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Oncology. Recurrent topics in Vincent Chow's work include Biosimilars and Bioanalytical Methods (26 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Pharmaceutical studies and practices (12 papers). Vincent Chow is often cited by papers focused on Biosimilars and Bioanalytical Methods (26 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Pharmaceutical studies and practices (12 papers). Vincent Chow collaborates with scholars based in United States, United Kingdom and Netherlands. Vincent Chow's co-authors include Richárd Márkus, Vladimir Hanes, Gary Chan, Sriram Krishnaswami, Nan Zhang, M. Boy, Primal Kaur, Zhiying Pan, Michael Moxness and Robert R. LaBadie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Vincent Chow

43 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent Chow United States	15	354	219	126	124	109	44	639
Elaine Murray United States	9	200 0.6×	198 0.9×	22 0.2×	104 0.8×	42 0.4×	11	716
Tomasz Sarosiek Poland	14	193 0.5×	313 1.4×	109 0.9×	21 0.2×	76 0.7×	38	754
Anna López‐Ferrer Spain	19	630 1.8×	84 0.4×	63 0.5×	179 1.4×	76 0.7×	55	935
Irène Teyssandier France	6	470 1.3×	186 0.8×	235 1.9×	131 1.1×	82 0.8×	8	1.2k
Weili Sun United States	12	100 0.3×	164 0.7×	130 1.0×	12 0.1×	64 0.6×	29	891
Gordon Moody United States	11	139 0.4×	303 1.4×	156 1.2×	37 0.3×	11 0.1×	24	836
Antònia Sampol Spain	14	161 0.5×	189 0.9×	44 0.3×	41 0.3×	18 0.2×	60	731
Herbert Struemper United States	14	233 0.7×	127 0.6×	167 1.3×	137 1.1×	17 0.2×	35	469
Marek Krogulec United States	6	194 0.5×	134 0.6×	38 0.3×	493 4.0×	18 0.2×	10	675
Christine McIntyre Switzerland	14	146 0.4×	303 1.4×	253 2.0×	9 0.1×	40 0.4×	31	634

Countries citing papers authored by Vincent Chow

Since Specialization

Citations

This map shows the geographic impact of Vincent Chow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Chow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Chow more than expected).

Fields of papers citing papers by Vincent Chow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Chow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Chow. The network helps show where Vincent Chow may publish in the future.

Co-authorship network of co-authors of Vincent Chow

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Chow. A scholar is included among the top collaborators of Vincent Chow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Chow. Vincent Chow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chow, Vincent, et al.. (2025). Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong. Infection and Drug Resistance. Volume 18. 1325–1337. 4 indexed citations

Chow, Vincent, Daniel T. Mytych, Andrew Blauvelt, et al.. (2024). P1081 Pharmacokinetics and immunogenicity of the ustekinumab biosimilar candidate ABP 654 in patients with moderate-to-severe plaque psoriasis. Journal of Crohn s and Colitis. 18(Supplement_1). i1932–i1932. 2 indexed citations

Kulasekararaj, Austin, et al.. (2023). Efficacy of Parallel and Crossover Analysis As Well As Pharmacokinetic Similarity Were Confirmed between ABP 959 and Eculizumab Reference Product in Patients with PNH. Blood. 142(Supplement 1). 4092–4092. 1 indexed citations

Doshi, Sameer, Hui Wang, & Vincent Chow. (2022). Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling. Clinical Therapeutics. 44(1). 111–122. 5 indexed citations

McBride, Helen J., Vincent Chow, Palanisamy Kanakaraj, et al.. (2021). Non-clinical similarity of biosimilar ABP 798 with rituximab reference product. Biologicals. 72. 42–53. 2 indexed citations

Chow, Vincent, et al.. (2021). Use of nonclinical toxicity studies to support biosimilar antibody development. Regulatory Toxicology and Pharmacology. 122. 104912–104912. 3 indexed citations

Reinisch, Walter, Stanley Cohen, Monica Ramchandani, et al.. (2021). A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar. Advances in Therapy. 39(1). 44–57. 2 indexed citations

Hanes, Vladimir, et al.. (2021). A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects. Cancer Chemotherapy and Pharmacology. 88(5). 879–886. 2 indexed citations

Burmester, Gerd R, et al.. (2020). A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis. Clinical Pharmacology in Drug Development. 9(8). 1003–1014. 10 indexed citations

10.

Hanes, Vladimir, Vincent Chow, Zhiying Pan, & Richárd Márkus. (2018). A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemotherapy and Pharmacology. 82(5). 899–905. 16 indexed citations

11.

Carducci, Michael A., Montaser Shaheen, Ben Markman, et al.. (2018). A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. 36(6). 1060–1071. 33 indexed citations

12.

Márkus, Richárd, Vincent Chow, Zhiying Pan, & Vladimir Hanes. (2017). A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemotherapy and Pharmacology. 80(4). 755–763. 36 indexed citations

13.

Hanes, Vladimir, Vincent Chow, Nan Zhang, & Richárd Márkus. (2017). A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemotherapy and Pharmacology. 79(5). 881–888. 32 indexed citations

14.

Kaur, Primal, Vincent Chow, Nan Zhang, et al.. (2016). A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Annals of the Rheumatic Diseases. 76(3). 526–533. 65 indexed citations

15.

Alvarez‐Núñez, Fernando, Vincent Chow, Dominick Daurio, et al.. (2015). Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility. Journal of Pharmaceutical Sciences. 104(4). 1522–1532. 14 indexed citations

16.

Krishnaswami, Sriram, M. Boy, Vincent Chow, & Gary Chan. (2014). Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clinical Pharmacology in Drug Development. 4(2). 83–88. 35 indexed citations

17.

Krishnaswami, Sriram, Vincent Chow, M. Boy, Cunshan Wang, & Gary Chan. (2013). Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease. The Journal of Clinical Pharmacology. 54(1). 46–52. 44 indexed citations

18.

Dodds, Mike, Vincent Chow, Richárd Márkus, et al.. (2013). The Use of Pharmacometrics to Optimize Biosimilar Development. Journal of Pharmaceutical Sciences. 102(11). 3908–3914. 5 indexed citations

19.

Cohen, Stanley, Samuel H. Zwillich, Vincent Chow, Robert R. LaBadie, & Bethanie Wilkinson. (2009). Co‐administration of the JAK inhibitor CP‐690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. British Journal of Clinical Pharmacology. 69(2). 143–151. 38 indexed citations

20.

Weimar, Willem, Robert S. Gaston, Daniel C. Brennan, et al.. (2008). Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. American Journal of Transplantation. 8(8). 1711–1718. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact